Introduction {#s1}
============

The number of pregnancies complicated by gestational diabetes mellitus (GDM) is increasing worldwide. Depending on the diagnostic criteria and ethnic populations, the incidences range from ∼1 to over 10% ([@GAT020C8]). In industrialized countries, approximately every 10th pregnancy is affected and without universal screening programs, many of them may remain unrecognized and untreated ([@GAT020C79]). GDM and type 2 diabetes share a common etiology. The increasing food supply to the fetus during late pregnancy creates a diabetogenic situation (moderate peripheral insulin resistance) for the mother. GDM presents in women without pregestational diabetes, when the maternal β-cell function cannot adapt to the increased insulin demand of late pregnancy; usually it disappears again after delivery ([@GAT020C38]). GDM is diagnosed by an elevated fasting plasma glucose and/or a pathological oral glucose tolerance test ([@GAT020C2]; [@GAT020C20]). Many pregnant women with GDM can control their glucose levels with a diet, consisting of ∼45% carbohydrate, 30--35% fat and up to 20% protein, although some women require insulin therapy. Common risk factors for GDM are maternal obesity and a family history of diabetes ([@GAT020C57]; [@GAT020C38]; [@GAT020C96]). Several genetic variants, including genes for β-cell function have been associated with GDM ([@GAT020C85]; [@GAT020C84]). However, in addition to genetics, overnutrition and physical inactivity, other factors, in particular epigenetic programming of the metabolism early in life appear to play a predominant role ([@GAT020C35]; [@GAT020C44]; [@GAT020C74]; [@GAT020C78]).

Children born to mothers with GDM have an increased risk for stillbirth, perinatal complications and notably high birthweight ([@GAT020C88]; [@GAT020C46]). In contrast to the well-known teratogenic effects of periconceptional hyperglycemia in mothers with type 1 or 2 diabetes ([@GAT020C42]; [@GAT020C19]), hyperglycemia in mothers with GDM usually develops during the third trimester when organogenesis is largely completed. Therefore, congenital malformations are not significantly increased. Fetal visceromegaly and macrosomia in neonates exposed to GDM may be largely due to the growth-promoting effects of fetal insulin which is produced in response to the high levels of maternal glucose (overstimulation of fetal β-cells). Since [@GAT020C6] first noted the association between fetal growth (as a surrogate marker of fetal nutrition) and the occurrence of metabolic disorders later in life, a large number of epidemiologic studies demonstrated that the infants of diabetic mothers are more susceptible to complex diseases, including obesity ([@GAT020C24]), type 2 diabetes ([@GAT020C17]), metabolic and cardiovascular complications ([@GAT020C104]; [@GAT020C72]), and even cancer ([@GAT020C105]). Discordant human siblings born before and after the development of maternal diabetes ([@GAT020C22]) and embryo transfer experiments in rats ([@GAT020C37]) provided compelling evidence that these later life phenotypic consequences are caused by the diabetic environment *in utero*. Maternal obesity (with and without GDM) also leads to fetal overnutrition and appears to be a separate (confounding) risk factor for fetal macrosomia and metabolic disorders in childhood ([@GAT020C10]; [@GAT020C4]; [@GAT020C26]).

The phenomenon that adverse environmental exposures during early life, especially with regard to nutrition, increase the lifelong risk of many chronic diseases is now referred to as developmental programming or the 'Barker hypothesis' ([@GAT020C7]; [@GAT020C36]; [@GAT020C39]). Interestingly, there is a U-shaped relationship between birthweight, which reflects the uteroplacental supply of nutrients and hormones to the fetus, and disease risk ([@GAT020C45]; [@GAT020C5]; [@GAT020C15]). Transient overnutrition and undernutrition in early stages of life appear to have the same negative and long-lasting impact on setting (and fine-tuning) of the neuroendocrine control systems of the metabolism, leading to a lifelong increased morbidity. The mechanisms underlying this developmental programming of metabolic and cardiovascular diseases are still largely unclear. Epigenetic modifications are generally assumed to mediate gene--environment interactions, leading to persistent changes of gene regulation and metabolic pathways ([@GAT020C35]; [@GAT020C44]). Tissue culture experiments demonstrated that elevated insulin and glucose levels can interfere with the epigenetic programming machinery ([@GAT020C16]; [@GAT020C102]).

Epigenetics studies the inheritance of information beyond the DNA sequence. Biochemical changes, i.e. in forms of DNA methylation and histone modifications, control the spatial, temporal and parent-specific highly coordinated gene expression patterns. Each of the \>200 cell types of the body is endowed with a specific combination of silenced and expressed genes, which is established during development and differentiation and then stably inherited during cell divisions. The epigenome is the sum of the epigenetic modifications which bring a cellular phenotype into being. The most thoroughly studied epigenetic modification is the methylation of cytosine-phosphatidyl-guanine (CpG) sites. In contrast to non-coding regions of the genome where most CpGs are methylated to prevent retrotransposition activity ([@GAT020C106]), CpG islands in 5′ cis-regulatory regions of genes are usually unmethylated. Methylation of these CpG islands during development or disease processes is associated with post-translational histone modifications that lead to a locally condensed inactive chromatin structure and gene silencing ([@GAT020C53]; [@GAT020C101]). One important hallmark of the epigenome is its enormous plasticity in response to internal (i.e. during differentiation) and environmental factors ([@GAT020C32]; [@GAT020C33]). In this light, epigenetics is by far the most likely mechanism by which the intrauterine environment affects health and disease of the offspring.

Epigenetic effects of maternal nutritional environment on the offspring: evidence from animal models {#s2}
====================================================================================================

A number of elegant animal studies have shown that nutritional factors can modify the epigenome of the developing offspring. One of the most impressive examples is the Agouti viable yellow (*A^vy^*) mouse model, in which insertion of a transposable IAP element has created a metastable epiallele that can be turned on or off during early development. Depending on the degree of methylation at this IAP element, which is increased and decreased by methyl donor supplements ([@GAT020C99]) and endocrine disruptors ([@GAT020C3]) in the maternal diet, respectively, *A^vy^/a* offspring show a pseudoagouti (comparable to wild-type), a mottled (mosaic) or a viable yellow phenotype. The latter is characterized by the yellow coat color and susceptibility to metabolic diseases and cancer.

Neonatal overfeeding in rats was associated with epigenetic changes in the hypothalamic proopiomelanocortin (*Pomc*) and insulin receptor (*Insr*) genes that are important for the neurovegetative control of body weight and metabolism. The degree of hypermethylation was directly dependent on the glucose level ([@GAT020C80], [@GAT020C81]). Feeding pregnant rats a protein-restricted diet altered the DNA methylation and expression patterns of the glucocorticoid receptor (*Nr3c1*) and peroxisome proliferator-activated receptor alpha (*Ppara*) genes in the liver and heart of the offspring ([@GAT020C63], [@GAT020C64]; [@GAT020C91]). In a rat model for fetal programming of hypertension, exposure to a low-protein diet and/or maternal glucocorticoid in early pregnancy led to reduced methylation and increased expression of the adrenal angiotensin receptor (*At1b*) gene ([@GAT020C9]). Treatment of pregnant guinea pigs with glucocorticoids in late gestation induced changes in global DNA methylation and expression of several genes involved in epigenetic regulation in the offspring and subsequent generations ([@GAT020C21]). However, in general, even when statistical significance was reached, the absolute methylation differences in the above-mentioned studies were low. The offspring of mouse dams experiencing dietary protein restriction showed robust expression changes in several imprinted (i.e. *Gnas* and *Grb10*) and non-imprinted (*Ppara*) genes in the liver, whereas the DNA methylation patterns remained largely unaltered, suggesting that epigenetic mechanisms other than DNA methylation contribute to developmental programming ([@GAT020C51]).

Indeed, in a genome-wide chromatin immunoprecipitation survey, it was shown that streptozotocin-induced maternal diabetes and, independently, maternal consumption of a high-fat diet affected the histone H3 and H4 acetylation in chromatin of the mouse embryo. Increased H3K27 acetylation marks were enriched near neural tube defect genes, suggesting that epigenetic changes contribute to the teratogenic effects of maternal diabetes ([@GAT020C87]). In cultured cells, hyperglycemia increased histone acetylation via the citrate lyase pathway ([@GAT020C102]). A conceptually related study in primates ([@GAT020C1]) also revealed that *in utero* exposure to a caloric-dense high-fat maternal diet alters fetal chromatin structure (increased hepatic H3 acetylation).

Effects of maternal malnutrition in humans {#s3}
==========================================

In humans strong evidence for the long-lasting effects of an adverse early nutritional environment on health and disease comes from a well-studied cohort of men and women who were exposed *in utero* to the Dutch famine of 1944--1945. Comparison of individuals who had been exposed during early gestation and their unexposed siblings showed subtle blood methylation changes in several imprinted, i.e. the insulin-like growth factor 2 (*IGF2*), and non-imprinted, i.e. the leptin (*LEP*), genes ([@GAT020C47]; [@GAT020C95]). The peptide hormone leptin plays an essential role in the regulation of body weight. The prenatally exposed individuals suffered from increased risks for metabolic and cardiovascular diseases, accelerated cognitive ageing and schizophrenia ([@GAT020C94]; [@GAT020C76]; [@GAT020C93]; [@GAT020C23]). At least some of the observed epigenetic and phenotypic effects depended on the timing of exposure during gestation (with early gestation being the most vulnerable period) and sex of the exposed individual ([@GAT020C86]; [@GAT020C95]). The observation of an increased neonatal adiposity in the offspring of exposed women suggests possible transgenerational effects of maternal undernutrition ([@GAT020C77]).

During the rainy season in rural Gambia, pregnant women experience deficiencies in several micronutrients and the resultant offspring display a high incidence of low birthweight, and childhood morbidity and mortality. Maternal micronutrient supplementation (with vitamins and minerals) around the time of conception had widespread and sex-specific effects on the epigenome of the offspring. Some of the observed DNA methylation changes were shown to persist into early infancy ([@GAT020C18]; [@GAT020C56]). Similar to fetal adaption to maternal malnutrition, neonates with intrauterine growth restriction exhibited specific changes in DNA methylation, in particular the hepatocyte factor 4 alpha (*HNF4A*) gene ([@GAT020C28]). Consistent with evidence from animal models, these studies in humans suggest that the nutritional environment in which the human embryo and fetus develops can influence the epigenetic programming of gene activity in later life.

Epigenetic effects of gestational diabetes {#s4}
==========================================

Using bisulfite pyrosequencing, we have analyzed the methylation levels of seven imprinted genes involved in pre- and post-natal growth, four genes involved in energy metabolism, one anti-inflammatory gene, one tumor suppressor gene, one pluripotency gene and two repetitive DNA families in umbilical cord blood and placenta of neonates of mothers with dietetically treated or insulin-dependent GDM and controls without GDM ([@GAT020C30]). The maternally imprinted mesoderm-specific transcript (*MEST*) and the non-imprinted glucocorticoid receptor *NR3C1* genes showed subtly (in the order of several percentage points) but significantly decreased methylation levels in both GDM groups, compared with controls, in both analyzed tissues. In a conceptually related study, a lower DNA methylation level of the adiponectin (*ADIPOQ*) gene in fetal placenta tissue was correlated with maternal hyperglycemia ([@GAT020C11]).

Mouse knockout experiments have shown that the paternally expressed *Mest* gene plays a role in growth of the embryo and placenta as well as in development of a 'social brain' after birth ([@GAT020C62]). Transgenic *Mest* overexpression led to an enlargement of adipocytes and fat mass expansion ([@GAT020C54]). The endogenous *Mest* gene can be up-regulated by early overnutritional environment ([@GAT020C60]). Variations of *Mest* expression in genetically identical mice (before overnutrition) correlated with the development of diet-induced adiposity ([@GAT020C59]). The glucocorticoid receptor NR3C1, which was also susceptible to metabolic programming, is a transcription factor involved in many cellular processes, including proliferation and differentiation. In the rat model, environmentally (i.e. by maternal diet or early care) induced epigenetic changes in *Nr3c1* have been associated with long-term effects on metabolism, stress response and behavior ([@GAT020C100]; [@GAT020C64]). Similarly in humans, prenatal ([@GAT020C75]) and childhood experiences ([@GAT020C70]; [@GAT020C97]) of adverse parental behavior were associated with blood and brain *NR3C1* methylation changes, increased stress reactivity and risk for adult psychopathology. The circulating hormone ADIPOQ is secreted abundantly by adipocytes and has anti-inflammatory, anti-atherogenic and anti-diabetic (insulin-sensitizing) effects ([@GAT020C82]).

In addition to single copy genes, interspersed ALU repeats also showed a slightly (1% point) lower methylation level in cord blood and placenta of neonates who were exposed to GDM *in utero* ([@GAT020C30]). Transposable ALU elements comprise ∼10% of the human genome and, when inserted into promoters/first exons, can affect the regulation of gene expression ([@GAT020C50]). This suggests that hyperglycemia during pregnancy affects multiple loci in the fetal epigenome, which is not unexpected considering the manifold long-term phenotypic effects of an adverse fetal environment.

In humans, it is difficult to study the long-term consequences of altered methylation patterns in blood and/or placenta of neonates. We found significantly decreased blood *MEST* methylation levels in adults with morbid obesity, compared with normal-weight controls ([@GAT020C30]). The observation that *MEST* is specifically up-regulated in fat tissue of obese individuals ([@GAT020C58]) supports the view that intrauterine malprogramming of *MEST* contributes to obesity predisposition throughout life. [@GAT020C40] analyzed the methylation levels of five candidate genes (selected on the basis of animal studies and methylation array data) in umbilical cord tissue of healthy newborns and found an association of perinatal promoter methylation of the retinoid receptor α (*RXRA*) and endothelial nitric oxide synthetase (*NOS3*) genes with childhood adiposity at 9 years of age.

Limitations {#s5}
===========

In general, epigenetic changes due to maternal nutritional exposure are relatively small at the single gene level but appear to be widespread ([@GAT020C95]; [@GAT020C56]; [@GAT020C87]; [@GAT020C30]). Similar to the genetic variants that have been identified by genome-wide association studies (GWASs), the effect sizes of epigenetic markers that have been associated with an adverse periconceptional and prenatal environment may be small. Thus, consistent with the multifactorial threshold model for complex diseases, stochastic and environmentally induced epigenetic variations in many genes and pathways may determine the disease risk later in life. Highly penetrant disease-causing epimutations, i.e. in imprinted genes are very rare ([@GAT020C51]; [@GAT020C29]) and, evidently, cannot explain the fetal programming of adult disease.

An additional shortcoming is that DNA methylation patterns are cell type and tissue-specific. At least in humans, it is not possible to study the target tissues for metabolic disease, i.e. the hypothalamic--pituitary--adrenal axis, fat, liver, skeletal muscle and/or pancreatic islets. It is generally assumed that the observed epigenetic changes in accessible tissues such as blood or placenta can identify genes susceptible to fetal programming in the target tissues. Even animal studies so far largely ignored that the cell composition of a tissue may vary between groups, i.e. exposed and unexposed individuals.

Because intrauterine exposures are nearly impossible to quantify in time and space and each exposure has the potential to induce numerous changes with small effect sizes, most likely interacting with each other, it is difficult to prove that the epigenetic changes that have been associated with different developmental experiences are directly involved in the pathogenesis of chronic disease later in life and not just a consequence of the pathology. One of the most impressive examples of the phenotypic consequences of aberrant methylation patterns is epigenetic silencing of tumor suppressor genes such as *BRCA1* that plays an important role in breast and ovarian cancer development ([@GAT020C31]; [@GAT020C43]). *In vitro* methylation and transfection assays showed that repression of the *BRCA1* promoter directly depends on the number of methylated CpGs ([@GAT020C65]). It is usually the density of methylated CpGs rather than individual CpGs that turns a promoter or an imprinting control region off ([@GAT020C101]). Similarly, inactivation of the somatostatin gene in gastric cancers is characterized by an inverse correlation between promoter methylation level and mRNA expression ([@GAT020C52]). It is plausible to assume that the methylation changes that have been linked to different nutritional exposures also alter gene expression and, thus, phenotypic information.

Conclusions {#s6}
===========

So far, the main focus of reproductive medicine has been on pregnancy rates and the outcome at birth. The long-term consequences of environmental factors around the time of conception and during pregnancy are largely neglected. The epigenome is most plastic in early stages of embryo development when parent-specific genome reprogramming occurs ([@GAT020C69]; [@GAT020C83]). This plasticity is then steadily decreasing during prenatal and post-natal life ([@GAT020C39]). If gestational hyperglycemia can permanently increase an individual\'s risk of chronic disorders in later stages of life, we should be more concerned about the possible adverse effects of assisted reproductive technologies (ART), in particular embryo culture on adult health and disease ([@GAT020C29]). In *in vitro* produced lambs and calves, suboptimal embryo culture has been linked to aberrant expression of imprinted genes, causing large offspring syndrome ([@GAT020C107], [@GAT020C108]). Similarly, mouse studies provided clear evidence that embryo culture conditions can affect epigenetic gene regulation and cause adverse phenotypic changes, including organomegaly, glucose intolerance, as well as neurodevelopmental and behavioral alterations ([@GAT020C55]; [@GAT020C27]; [@GAT020C34]; [@GAT020C67]; [@GAT020C14]).

A systematic comparison of mouse embryo responses to different human ART culture protocols showed significant differences in blastocyst and fetal developmental rates, demonstrating the dramatic impact of the culture system on somatic differentiation ([@GAT020C68]; [@GAT020C89]). Because gametogenesis and embryonic development differ considerably in rodents and humans, mouse oocyte and embryo assays do not necessarily allow one to extrapolate to the human situation. Owing to the striking similarities with human development, bovine oocytes and embryos are increasingly used as models for human ART ([@GAT020C71]; [@GAT020C103]; [@GAT020C48]). For legal and ethical reasons, it is not possible to use large numbers of human ART and non-ART embryos to systematically study the epigenetic and phenotypic effects of early human life conditions. Because it is problematic to assess the epigenetic safety of human ART protocols using rodent or large animal models, manipulation of oocyte and embryo should be restricted to a minimum or to the advantage of a specific technique (i.e. selection during embryo culture and blastocyst transfer) and must outweigh possible negative epigenetic effects (i.e. during extended embryo culture). Therefore, long-term epidemiologic studies on the lifelong risks of different ART protocols for metabolic, cardiovascular, neurodevelopmental, behavioral and other complex diseases are urgently needed. One important prerequisite for such studies is that future medical records of an individual also include information on parental infertility, mode of conception, and in the case of ART, which protocols have been used.

It is now widely accepted that an adverse periconceptional and intrauterine environment is associated with epigenetic malprogramming of the fetal metabolism and predisposition to chronic, in particular, metabolic disorders later in life ([@GAT020C7]; [@GAT020C36]; [@GAT020C35]; [@GAT020C44]; [@GAT020C79]). Considering that in highly industrialized Western countries, up to 20% of women are obese at the start of pregnancy and up to 10% develop GDM during late pregnancy ([@GAT020C8]; [@GAT020C57]), fetal overnutrition with glucose, free fatty acids and amino acids and the resulting hyperinsulinism may play a major role in the etiopathogenesis and current epidemics of obesity and type 2 diabetes (Fig. [1](#GAT020F1){ref-type="fig"}). The genetic variants that have been identified so far in large GWASs explain only a small fraction of the considerable heritability of type 2 diabetes and obesity (26 and 70%, respectively; [@GAT020C49]; [@GAT020C66]). In our opinion, modulations of the fetal epigenome by maternal diabetes and/or obesity provide the most reasonable mechanism for non-genetic intergenerational transmission of the phenotype. The missing heritability of complex disorders may be largely attributable to epigenetic inheritance. Figure 1The cycle of metabolic disease epidemics. Fetal overnutrition due to GDM and/or maternal obesity leads to epigenetic changes in the exposed offspring. As an example, the box plot diagrams on top show the significantly different distribution of placenta *MEST* methylation values in newborns of mothers with dietetically treated D-GDM and insulin-treated I-GDM, compared with newborns of mothers without GDM. *MEST* hypomethylation may foreshadow diet-induced obesity. Similarly, epigenetic changes in numerous other genes may increase the lifelong metabolic disease susceptibility and, thus, the likelihood for a new generation of mothers with GDM and/or obesity, feeding the vicious cycle. Consistent with the decreasing plasticity of the epigenome, the effect of possible interventions to break the cycle can be expected to be larger in the periconceptional and prenatal period than after birth, during infancy and in adulthood.

To prevent metabolic disease epidemics, it is important to break the vicious cycle (Fig. [1](#GAT020F1){ref-type="fig"}) in which mothers with GDM and/or obesity have babies with epigenetic changes who are prone to develop metabolic disease later in life and, thus, give rise to a new generation of mothers with GDM/obesity. Considering the enormous plasticity of the epigenome during late stages of oocyte and early stages of embryo development ([@GAT020C29]), one could hypothesize that the best time for action is periconceptionally. However, the true challenge resides in finding a solution as to how we can optimize the periconceptional environment with our currently limited knowledge on the underlying mechanisms and the optimum supply with macro- and micronutrients around conception, both *in vivo* and *in vitro*. In the sheep model it was shown that micronutrient deficiencies, such as folic acid and vitamin B12 during the periconceptional period cause widespread epigenetic alterations and long-term health implications for the offspring ([@GAT020C90]). Dietary restriction of folic acid, methionine, choline, and/or vitamin B12 can perturb transmethylation pathways (i.e. for DNA methylation) by decreasing the availability of methyl groups ([@GAT020C73]). One interesting study on a relatively small number of Gambian women ([@GAT020C56]) suggests that micronutritional supplementation around the time of conception can affect the epigenome of the offspring ([@GAT020C56]), possibly reducing fetal maladaption to inadequate nutrition during gestation. This is consistent with animal studies demonstrating that methyl supplementation of the maternal diet (i.e. with folic acid) can at least to some extent prevent a metabolic phenotype in the offspring ([@GAT020C99]; [@GAT020C63], [@GAT020C64]; [@GAT020C12]).

From a clinical point of view, it is important to note that effective treatment of maternal diabetes ([@GAT020C25]; [@GAT020C79]) as well as large weight loss of obese women before pregnancy ([@GAT020C61]; [@GAT020C92]) appears to reduce the metabolic disease risk in the offspring. To prevent materno-fetal hyperglycemia and fetal hyperinsulinism, it is important to screen all pregnant women for disturbed glucose tolerance and to normalize a diabetic intrauterine environment by dietetic measures or insulin therapy. At the same time, we need biomarkers that help to assess adverse intrauterine exposures and lasting disease predispositions. This requires a more systematic comparison of fetal epigenomes using genome-wide methylation arrays or reduced representation bisulfite sequencing. Since the effect size of a single methylation change, i.e. in the *MEST* gene is low, we have to develop fetal and perinatal methylation profiles with more predictive power.

In contrast to genetic mutations/variants, epimutations are in principle reversible. This offers the exciting possibility to eventually compensate the epigenetic effects of an adverse intrauterine environment by pharmacological, dietary or behavioral interventions after birth. In the rat model of maternal undernutrition, neonatal leptin treatment and pre-weaning growth hormone treatment could prevent fetal programming of adult obesity, hypertension and vascular dysfunction ([@GAT020C98]; [@GAT020C41]). Similarly, increasing folic acid intake during the juvenile-pubertal period was shown to reverse the negative phenotypic effects of prenatal undernutrition ([@GAT020C13]). So far, in humans conclusive studies on the reversibility of fetal programming by specific post-natal treatments are missing. Breast feeding is generally recommended to avoid post-natal overfeeding ([@GAT020C79]). However, much more research is needed toward an optimal post-natal environment/management to correct adverse prenatal experiences.

Authors\' roles {#s7}
===============

All authors provided substantial contributions to the review conception and data interpretation. T.H. wrote and H.L. and U.Z. critically revised the manuscript. All authors approved the submitted manuscript.

Funding {#s8}
=======

T.H. and U.Z. were supported by research grants (HA 1374/15-1 and ZE 442/5-2) from the German Research Foundation. Funding to pay the Open Access publication charges for this article was provided by the operating revenues of the Würzburg Institute of Human Genetics.

Conflict of interest {#s9}
====================

None declared.
